Bai Li Tian Heng: T-Bren has been included in the list of breakthrough therapy varieties.

Baili Tianheng announced that its independently developed innovative biopharmaceutical T-Bren has been included in the list of breakthrough therapeutic varieties, for the treatment of HER2 positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma patients who have failed previous first-line anti-HER2 therapy and first-line standard chemotherapy. T-Bren has shown significant anti-tumor efficacy in clinical trials and has the best potential among similar drugs. Currently, T-Bren is being tested in 14 clinical trials at home and abroad, covering multiple HER2 positive tumor indications.